Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

MariTide, Amgen's candidate for obesity treatment ... Furthermore, Amgen's diverse approach to cancer treatment, including both small molecule and biologic therapies, increases the likelihood ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

The Phase II study of MariTide is progressing well ... a first-in-class STEAP1 CD3 bispecific molecule, into Phase III clinical development for post-taxane metastatic castrate-resistant prostate ...

“In our mind, Boehringer looks to be the third large pharma company that can actually enter the obesity space with a very differentiated molecule ... In that sense, VK-2735 could compete with MariTide ...